Helicore Biopharma Launches from Stealth Mode with $65M Series A Round

  • Helicore Biopharma has completed a $65 million Series A financing round.
  • The funding will support clinical trials for its investigational therapies targeting obesity and related conditions.

Helicore Biopharma, a company focused on developing novel treatments for obesity and related conditions, has announced the completion of a $65 million Series A financing round. The financing was co-led by founding investor Versant Ventures and OrbiMed, with additional participation from Longitude Capital and Wellington Management.

The funds will support Helicore’s clinical stage monoclonal antibody, HCR-188, which is designed to target glucose-dependent insulinotropic peptide (GIP) to treat obesity. The company’s portfolio also includes antibody conjugates aimed at specific obesity subpopulations, including combinations with GLP-1.

“We’ve rapidly advanced a differentiated portfolio that may deliver superior treatment outcomes through enhanced efficacy, tolerability, and convenient dosing regimens,” said Gerrit Klaerner, Ph.D., President and CEO of Helicore.

In addition to advancing HCR-188, the company is exploring combinations with GLP-1 to provide comprehensive benefits for patients, including cardiometabolic advantages. Helicore’s scientific approach is based on human genetics insights and preclinical data, which suggest the potential for higher-quality weight loss and enhanced satiety.

With the leadership of Klaerner and Klaus Veitinger, M.D., Ph.D., as Chairman, Helicore is poised for rapid progress in 2025, aiming to make strides in advancing both HCR-188 and its exciting portfolio of antibody conjugates.

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.